{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Time from study entry until 2nd instance of disease progression. Progression is determined by the International Myeloma Working Group Criteria. Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms.","groups":[{"description":"Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.\n\nClarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG000","title":"BiRD Treatment Regimen"},{"description":"Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG001","title":"Rd Treatment Regimen"}],"populationDescription":"Data not collected due to early trial termination due to low accrual.","reportingStatus":"POSTED","timeFrame":"approximately 5 years","title":"Number of Months to Progression-Free Survival 2","type":"SECONDARY"}